Prognostic Value of SUVmax Measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Gallbladder Cancer

被引：6

作者：

Hwang J.P. ^{[1
]}

Lim I. ^{[1
,2
]}

Na I.I. ^{[3
]}

Cho E.H. ^{[4
]}

Kim B.I. ^{[1
,2
]}

Choi C.W. ^{[1
,2
]}

Lim S.M. ^{[1
,2
]}

机构：

[1] Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Nowon Gu, Seoul, 139-706

[2] Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences (KIRAMS), Nowon Gu, Seoul

[3] Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Nowon Gu, Seoul

[4] Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Nowon Gu, Seoul

来源：

Nuclear Medicine and Molecular Imaging | 2014年 / 48卷 / 2期

基金：

新加坡国家研究基金会;

关键词：

FDG; Gallbladder cancer; PET; Survival;

D O I：

10.1007/s13139-013-0255-z

中图分类号：

学科分类号：

摘要：

Objective: The aim of this study is to investigate the prognostic value of F-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET)/computed tomography (CT) in gallbladder cancer patients. Methods: From June 2004 to June 2010, a total of 50 patients with gallbladder cancer who underwent diagnostic staging with F-18 FDG PET/CT following curative or palliative treatments were retrospectively evaluated. For the analysis, all patients were classified by age, sex, maximum standardized uptake value (SUVmax), lymph node (LN) or distant metastasis, serum level of CA19-9 and CEA, type of treatment and American Joint Committee on Cancer (AJCC) stage. Results: The median survival for the 50 patients was 245 days and the median SUVmax in PET/CT was 8.3 (range, 0-19.7). Patients with SUVmax < 6 survived significantly longer than patients with SUVmax ≥ 6 (median 405 days vs 203 days, p = 0.0400). On Kaplan-Meier analysis, SUVmax (p = 0.0400), stage (p = 0.0001), CA19-9 (p = 0.013), CEA (p = 0.006), LN metastasis (p = 0.0001), distant metastasis (p = 0.0020), type of treatment (p = 0.0001) were significantly associated with overall survival. Multivariate analysis study revealed that the patients with lower SUVmax measured from initial staging PET/CT (p = 0.0380), no LN metastasis (p = 0.0260), a lower stage (p = 0.026) and curative treatment (p = 0.0005) had longer survivals. Conclusions: The present study shows that SUVmax on F-18 FDG PET/CT can provide prognostic information in patients with gallbladder cancer. © 2013 Korean Society of Nuclear Medicine.

引用

页码：114 / 120

页数：6

共 24 条

[1]

Donohue J.H., Present status of the diagnosis and treatment of gallbladder carcinoma, J Hepatobiliary Pancreat Surg, 8, pp. 530-534, (2001)

[2]

Butte J.M., Redondo F., Waugh E., Meneses M., Pruzzo R., Parada H., Et al., The role of PET-CT in patients with incidental gallbladder cancer, HPB (Oxford), 11, pp. 585-591, (2009)

[3]

Ouchi K., Owada Y., Matsuno S., Sato T., Prognostic factors in the surgical treatment of gallbladder carcinoma, Surgery, 101, pp. 731-737, (1987)

[4]

Sacks A., Peller P.J., Surasi D.S., Chatburn L., Mercier G., Subramaniam R.M., Value of PET/CT in the management of primary hepatobiliary tumors, part 2, AJR Am J Roentgenol, 197, pp. 260-265, (2011)

[5]

Yoo J., Choi J.Y., Lee K.T., Heo J.S., Park S.B., Moon S.H., Et al., Prognostic significance of volume-based metabolic parameters by <sup>18</sup> F-FDG PET/CT in gallbladder carcinoma, Nucl Med Mol Imaging, 46, pp. 201-206, (2012)

[6]

Covera C.U., Blumgart L.H., Akhurst T., DeMatteo R.P., D'Angelica M., Fong Y., Et al., 18 F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer, J Am Coll Surg, 206, pp. 57-65, (2007)

[7]

Lee S.W., Kim H.J., Park J.H., Park D.I., Cho Y.K., Sohn C.I., Et al., Clinical usefulness of 18 F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma, J Gastroenterol, 45, 5, pp. 560-566, (2010)

[8]

Petrowsky H., Wildbrett P., Husarik D.B., Hany T.F., Tam S., Jochum W., Et al., Impact of integrated positron emission tomography on staging and management of gallbladder cancer and cholangiocarcinoma, J Hepatol, 45, pp. 43-50, (2006)

[9]

Maldonado A., Gonzalez-Alenda F.J., Alonso M., Sierra J.M., PET-CT in clinical oncology, Clin Transl Oncol, 9, pp. 494-505, (2007)

[10]

Higashi K., Ueda Y., Arisaka Y., Sakuma T., Nambu Y., Oquchi M., Et al., 18 F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small-cell lung cancer, J Nucl Med, 43, pp. 39-45, (2002)

← 1 2 3 →